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and specific oligosaccharides (Sialyl Lewis X: SLex) on
PMNs. This may contribute to the no-reflow phenome-
non, which has been demonstrated to be important in
cerebral injury after reperfusion. Prevention of selectin-
mediated PMN adherence could potentially reduce
PMN-mediated ischemia/reperfusion injury. The cur-
N eutrophil (PMN) adhesion to endothelium is impor-tant in mediating ischemia/reperfusion injury dur-
ing and after cardiopulmonary bypass (CPB). Tethering
and rolling of PMNs on activated endothelium is the
initial step in the inflammatory process and is mediated
by interactions between selectins on endothelial cells
Background: The initial step in the inflammatory process, which can be
initiated by cardiopulmonary bypass and by ischemia/reperfusion, is
mediated by interactions between selectins on endothelial cells and on
neutrophils. We studied the effects of selectin blockade using a novel
Sialyl Lewis X analog (CY-1503) on recovery after deep hypothermic
circulatory arrest in a piglet model. Methods: Twelve Yorkshire piglets
were subjected to cardiopulmonary bypass, 30 minutes of cooling, 100
minutes of circulatory arrest at 15°C, and 40 minutes of rewarming.
Five animals received a bolus of 60 mg/kg of CY-1503 and an infusion (3
mg/kg per hour) for 24 hours from reperfusion (group O), and 7 ran-
domly selected control piglets received saline solution (group C). Body
weight and total body water content were evaluated 3 hours and 24
hours after reperfusion by a bio-impedance technique. Neurologic
recovery of animals was evaluated daily by neurologic deficit score (0 =
normal, 500 = brain death) and overall performance categories (1 = nor-
mal, 5 = brain death). The brain was fixed in situ on the fourth postop-
erative day and examined by histologic score (0 = normal, 5+ = necrosis)
in a blinded fashion. Results: Two of 7 animals in group C died. The neu-
rologic deficit score was significantly lower in group O than in group C
(postoperative day 1, P < .001; postoperative day 2, P = .02). The over-
all performance category was significantly lower in group O than in
group C on postoperative day 2 (P = .01). Percentage total body water
after cardiopulmonary bypass was significantly higher in group C than
in group O (P = .03). Histologic score tended to be higher in group C
than in group O, but this difference did not reach statistical significance
(group O = 0.5 ± 0.7; group C = 1.3 ± 1.9). Conclusion: Blockade of
selectin adhesion molecules by saturation with a Sialyl Lewisx analog
accelerates recovery after 100 minutes of deep hypothermic circulatory
arrest in a piglet survival model. (J Thorac Cardiovasc Surg 1999;
117:1204-11)
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rent study assessed the effect of selectin blockade using
a specific synthetic oligosaccharide analog of SLex
(CY-1503) in 5-week-old piglets undergoing 100 min-
utes of deep hypothermic circulatory arrest (DHCA) at
15°C.
Materials and methods
Experimental preparation. All animals received humane
care in compliance with the “Principles of Laboratory Animal
Care” formulated by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the National Institutes of Health (NIH
Publication No. 85-23, revised 1985).
Twelve 5-week-old Yorkshire pigs weighing 6.9 to 10.2 kg
(mean 7.8 kg) were anesthetized with intraperitoneal sodium
methohexital (45 mg/kg) and intubated. Each animal’s lungs
were ventilated with an inspired oxygen fraction of 0.4 at a
rate of 12 breaths/min with a pressure control ventilator
(Healthdyne model 105; Healthdyne Technologies, Marietta,
Ga). After bolus injection of fentanyl (25 m g/kg) and pancuro-
nium (0.5 mg/kg), anesthesia was maintained by continuous
intravenous infusion of fentanyl (25 m g/kg per hour), midazo-
lam (0.2 mg/kg per hour), and pancuronium (0.2 mg/kg per
hour) except during the circulatory arrest period. A brain tem-
perature probe (model HH-71T, Cole-Parmer Instrument Co,
Vernon Hills, Ill) was inserted into the subdural space through
an 18-gauge needle hole and secured on the skin. Nasopharyn-
geal, rectal, and brain temperatures were recorded throughout
the operation and in the postoperative period.
A catheter was placed into the superficial left femoral
artery for continuous blood pressure monitoring and arterial
blood gas sampling. The right femoral artery was exposed for
the arterial cannula in preparation for CPB. A right anterolat-
eral thoracotomy was performed in the third intercostal space.
The right atrium was exposed through the pericardium and
prepared for venous cannulation.
After systemic heparinization (300 IU/kg), an 8F arterial
cannula and 24F venous cannula were inserted into the right
femoral artery and right atrium, respectively. CPB was then
initiated and the animal was cooled to 15°C before 100 min-
utes of DHCA.
After 40 minutes of reperfusion and rewarming, CPB was
discontinued, and the arterial and venous cannulas were
removed when the animal’s condition became stable. Protamine
(6 mg/kg) was slowly administered intravenously. The chest
was closed in layers with a 20F chest tube left in place.
Anesthesia was maintained for 12 hours. After the chest tube
was removed, anesthesia was weaned and the animal extubated.
CPB technique. Details have been described previously.1
The pump prime consists of approximately 800 mL of elec-
trolyte solution (Normosol R, pH 7.4; Abbott Laboratories,
North Chicago, Ill) and 400 mL of homologous donor blood
to achieve a hematocrit value of 20% during CPB. The prime
is dosed with cefazolin sodium (25 mg/kg), methylpred-
nisolone (30 mg/kg), furosemide (0.25 mg/kg), and sodium
bicarbonate (10 mL).
Bypass flow was set at 100 mL/kg per minute. The animal
was immediately cooled to a nasopharyngeal temperature of
15°C and a rectal temperature of less than 18°C over 30 min-
utes by means of the pH-stat strategy. Phentolamine (0.2
mg/kg) was administered before cooling. After 30 minutes of
cooling, CPB was stopped for 100 minutes.
At a predetermined point for reperfusion, furosemide (0.25
mg/kg), mannitol (0.5 g/kg), and sodium bicarbonate (10 mL)
were administered to the pump. Reperfusion and rewarming
were restarted at 100 mL/kg per minute until a rectal temper-
ature of 36°C was achieved and for at least 40 minutes. The
heart was defibrillated as necessary at 25°C and blood was
given to maintain a hematocrit value above 25%. Ventilation
was resumed 10 minutes before weaning from CPB, with an
intermittent mandatory ventilation rate of 16 to 18
breaths/min. The animal was then weaned from CPB.
Experimental groups. Five animals received CY-1503
(group O), and 7 randomly selected control piglets received
saline solution (group C). In group O, a bolus of 60 mg/kg
was given in the pump prime and a continuous infusion of
CY-1503 (3 mg/kg per hour) was started at the onset of reper-
fusion after circulatory arrest and ended 24 hours after the
onset of CPB. In group C, the same volume of saline solution
was infused.
Data collection 
1. Body weight change. Body weight was measured before
anesthesia (baseline), 3 hours after CPB, on postoperative
day (POD) 1, and on POD 4 and was expressed as percent of
baseline measurement.
2. Total body water estimation by bio-electrical imped-
ance.2 Total body water content was estimated by bio-electri-
cal impedance (TBW 1/BEI) by means of the Weight
Manager Analyzer (BIA-101Q; RJL Systems, Inc, Clinton
Township, Mich). Percent change of total body water 3 hours
after CPB was calculated using the baseline body weight
before the operation.
3. Near-infrared spectroscopy. Details have been described
previously.3 In brief, a pair of near-infrared spectroscopy
fiberoptic optodes were attached to the head of the animal
after induction of anesthesia. The optode spacing was 3.0 cm
in a coronal plane. These optodes transmitted and detected
laser light at near-infrared wavelengths and were connected
to a near-infrared spectrometer (NIRO-500; Hamamatsu
Photonics KK, Hamamatsu, Japan), which calculated relative
concentration changes in oxygenated hemoglobin, deoxy-
genated hemoglobin, and oxidized cytochrome a,a3. These
data were collected continuously after induction of anesthe-
sia until 3 hours after the end of CPB.
4. Biochemical analysis. Blood samples were taken on the
first postoperative day. Aspartate aminotransferase, alanine
aminotransferase, lactate dehydrogenase, alkaline phos-
phatase, creatine kinase, and total bilirubin were measured.
5. Platelet count and white blood cell count. Blood samples
were taken before and immediately after coming off CPB and
on POD 1. Values were expressed as a percentage of baseline.
6. Neurologic and behavioral evaluations.4 Neurologic and
behavioral evaluations were performed at 24-hour intervals
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by observers blinded to the protocol, as described previously
in detail.4 Neurologic deficit score (NDS) and overall perfor-
mance category (OPC) were modified and used for the eval-
uation of animal recovery. In the NDS system, a score of 100
is assigned to each of 5 general components (central nervous
system function, respiration, motor and sensory function,
level of consciousness, and behavior). A total score of 500
indicates brain death, and a score of 0 is normal. The OPC
system establishes neurobehavioral criteria for 5 categories
from 1 to 5: 1 = normal, 2 = moderate disability, 3 = severe
disability, 4 = coma, and 5 = brain death.
7. Histologic evaluations. Details have been described
previously.4
8. Drug concentration. Blood samples were taken from the
pump prime and animals during CPB and at 1, 6, 7, 12, and
24 hours after CPB. Three milliliters of blood was drawn for
each sample and placed into a Vacutainer tube (Becton
Dickinson Vacutainer Systems, Franklin Lakes, NJ) contain-
ing sodium heparin preservative. The blood was mixed and
kept on ice after initial sampling. The samples were cen-
trifuged immediately for 15 minutes at 2000 rpm. The serum
was then transferred to polypropylene tubes and frozen at
–70°C for further analysis.
Statistical analysis. All results were expressed as mean ±
standard deviation of the mean and analyzed by a statistical
analysis software package (StatView version 4.5, Abacus
Concepts, Inc, Berkeley, Calif). The unpaired t test was used. 
Results
Experimental conditions (Table I). No differences
were found in body weight and hematocrit value during
CPB and on POD 1 between groups. There were no sta-
tistically significant differences in nasopharyngeal, rec-
tal, and brain temperatures during the cooling and
rewarming phases. There were no statistically signifi-
cant differences in brain temperature up to POD 4
between groups, although brain temperature tended to
be higher in group C than group O. There were no sig-
nificant differences in perfusion pressure during cool-
ing between the 2 groups, although pressure tended to
be lower in group O.
Operative results. Two of 7 animals in group C died
on PODs 1 and 2 as a result of arrhythmias caused by
heart failure. All data from these animals were exclud-
ed from subsequent analysis. All other animals were
extubated within 18 hours of the operation and sur-
vived for 4 days after the operation until put to death
for histologic examination.
Body weight change (Table II). Three hours after
CPB, body weight gain was significantly lower in
group O than in group C. On PODs 1 and 4 there were
no significant differences between groups.
Total body water content by bio-electrical imped-
ance (Table II). Calculated percentage total body water
Table I. Experimental conditions
Group C Group O t Test 
Group (mean ± SD) (mean ± SD) P value
Body weight (kg) 7.7 ± 0.9 7.9 ± 1.5 .78
Hematocrit (%)
Before operation 25.4 ± 2.9 25.8 ± 2.5 .78
Prime 16.1 ± 1.6 16.6 ± 1.1 .54
Before CA 20.0 ± 1.4 19.8 ± 1.3 .80
Before coming off CPB 23.8 ± 2.7 24.0 ± 2.3 .86
3 h after CPB 26.4 ± 1.5 27.2 ± 1.9 .44
POD 1 30.9 ± 3.9 28.0 ± 2.3 .12
Esophageal temperature (°C)
Cooling
0 min 35.1 ± 1.0 34.6 ± 1.8 .54
30 min 14.5 ± 1.8 13.1 ± 1.8 .20
Rewarming
0 min 16.0 ± 2.8 17.5 ± 2.0 .27
40 min 35.7 ± 1.7 36.9 ± 1.3 .16
Rectal temperature (°C)
Cooling
0 min 34.7 ± 0.9 35.9 ± 0.9 .04
30 min 17.2 ± 3.1 18.0 ± 1.8 .54
Rewarming
0 min 19.5 ± 2.6 17.1 ± 2.9 .18
40 min 34.8 ± 0.6 35.8 ± 0.9 .09
Brain temperature (°C)
Before CPB 36.9 ± 0.4 37.1 ± 1.3 .75
Cooling
0 min 34.2 ± 3.7 36.1 ± 2.6 .30
30 min 16.0 ± 2.2 16.0 ± 3.6 .99
Rewarming
0 min 16.4 ± 2.0 16.0 ± 2.2 .27
40 min 37.3 ± 1.4 37.6 ± 1.7 .74
After CPB
1 h 35.5 ± 1.3 37.1 ± 1.5 .09
2 h 36.6 ± 1.4 37.5 ± 1.0 .22
3 h 37.0 ± 0.9 37.2 ± 0.6 .58
4 h 36.7 ± 0.4 36.9 ± 1.5 .77
5 h 36.9 ± 0.4 36.2 ± 1.5 .40
6 h 37.0 ± 0.6 36.8 ± 1.2 .76
8 h 37.2 ± 0.6 36.9 ± 1.1 .52
10 h 37.3 ± 0.9 37.0 ± 1.0 .62
12 h 37.6 ± 0.9 37.4 ± 1.5 .77
24 h 39.2 ± 1.1 38.0 ± 0.9 .09
36 h 39.2 ± 0.5 38.1 ± 0.9 .06
48 h 39.1 ± 0.5 38.2 ± 1.2 .19
72 h 39.0 ± 0.4 38.6 ± 0.4 .17
96 h 39.0 ± 0.5 38.8 ± 0.7 .65
Perfusion pressure (mm Hg)
Cooling
10 min 58.4 ± 20.3 44.2 ± 4.0 .09
20 min 52.8 ± 15.2 40.2 ± 6.8 .07
30 min 49.3 ± 14.6 42.0 ± 8.0 .27
Rewarming
10 min 54.4 ± 15.2 48.0 ± 5.6 .31
20 min 78.3 ± 30.6 69.4 ± 22.0 .56
30 min 83.1 ± 24.6 76.0 ± 22.2 .60
40 min 79.1 ± 23.8 73.8 ± 19.1 .67
SD, Standard deviation; CA, circulatory arrest; CPB, cardiopulmonary bypass;
POD, postoperative day.
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content 3 hours after CPB was significantly lower in
group O.
Near-infrared spectroscopy (Fig 1, A, B, and C).
The oxygenated hemoglobin signal increased signifi-
cantly during cooling in both groups. From the onset of
DHCA, there was a decline in oxygenated hemoglobin
and cytochrome a,a3 signals in both groups, whereas
deoxygenated hemoglobin increased reciprocally (Fig
1). During DHCA and after CPB, cytochrome a,a3
recovery tended to be higher in group O than in group
C. However, 3 hours after CPB there were no differ-
ences between groups.
Enzymes (Table II). There was a statistically signifi-
cant difference in creatine kinase leakage on POD 1
between groups, with the level being lower with group
O. Levels of aspartate aminotransferase, alanine
aminotransferase, lactate dehydrogenase, and total bili-
rubin tended to be lower in group O, although no sig-
nificant differences were observed.
Platelet count and white blood cell count analysis
(Table II). Percentage platelet count was significantly
higher in group O just after coming off CPB. However,
there was no statistically significant difference in per-
cent white blood cell count between groups.
NDS (Table II, Fig 2, A and B). The NDS and OPC
demonstrated more rapid recovery in group O than in
group C. On POD 2, both the NDS and OPC score in
group O were significantly better than in group C. On
PODs 1 and 3, NDSs were better in group O. By POD
4, almost all animals showed normal recovery neuro-
logically.
Neuropathologic results. Neuropathologic damage
was evaluated, as in previous studies, primarily by the
presence of hypereosinophilic shrunken neurons with
karyorrhectic nuclei. This feature is evidence of recent
hypoxic ischemic injury. The hypoxic/ischemic injury
was more pronounced in group C, although the degree
of injury even in this control group of animals was
quite mild. Negligible injury was observed in group O,
although the differences between group O and group C
did not achieve statistical significance.
Drug concentration (Fig 3). In the pump prime the
initial concentration of CY-1503 was 648 ± 13 m g/mL. It
decreased immediately after the onset of CPB to 197 ± 5
m g/mL owing to hemodilution, and it decreased gradual-
ly during CPB. After the animal was weaned from CPB,
the concentration of CY-1503 was consistently stable at
30 to 50 m g/mL up to 24 hours after reperfusion.
Discussion
This study has shown that the administration of CY-
1503 accelerates neurologic recovery after 100 minutes
of DHCA in a piglet model, although histologic exam-
ination did not confirm significant improvement in pro-
tection of neural parenchymal tissue. This is perhaps
not surprising, because the sample size was small, con-
trol group histologic damage was not great, and the
observation period was limited. However, this study
did demonstrate evidence of possible blockade of
platelet adhesion to either endothelial cells or the pump
Table II. Results
Group C Group O t Test 
(mean ± SD) (mean ± SD) P value
Percent body weight
After CPB 115.5 ± 3.1 111.0 ± 1.4 .04*
POD 1 109.4 ± 4.3 109.0 ± 2.8 .84
POD 4 101.5 ± 8.0 107.0 ± 11.6 .41
Percent total body water
After CPB 123.2 ± 12.8 106.7 ± 1.6 .03*
POD 1 121.5 ± 13.6 120.6 ± 5.7 .60
Neurologic score
NDS
POD 1 214.3 ± 25.1 153.0 ± 20.8 .00*
POD 2 105.0 ± 45.6 45.0 ± 17.3 .02*
POD 3 36.7 ± 19.4 5.0 ± 7.1 .01*
POD 4 12.5 ± 14.7 0.0 ± 0.0 .09
OPC
POD 1 3.3 ± 0.5 3.0 ± 0.0 .17
POD 2 2.5 ± 0.5 1.4 ± 0.5 .01*
POD 3 1.5 ± 0.8 1.0 ± 0.0 .20
POD 4 1.2 ± 0.4 1.0 ± 0.0 .36
Enzyme
AST 153.7 ± 36.7 111.0 ± 37.8 .45
ALT 30.9 ± 4.2 18.2 ± 14.7 .51
LDH 1,349.0 ± 471.7 1,019.2 ± 252.1 .15
ALP 194.6 ± 40.3 189.8 ± 26.1 .81
CK 3,927.7 ± 1807.9 1,865.8 ± 499.7 .02*
Total bilirubin 0.5 ± 0.4 0.2 ± 0.1 .07
BUN 18.7 ± 7.7 16.8 ± 2.8 .56
Lactate
After CPB 6.9 ± 1.9 5.9 ± 0.8 .21
24 h after CPB 2.4 ± 0.5 2.0 ± 0.6 .31
SVO2 (%)
After CPB 78.0 ± 10.5 88.5 ± 2.1 .06
24 h after CPB 76.9 ± 4.5 83.0 ± 4.1 .07
WBC baseline 18,600 ± 4,150 18,400 ± 2,480 .95
Percent WBC
After CPB 78.2 ± 40.0 98.3 ± 65.6 .56
24 h after CPB 157.9 ± 81.6 164.7 ± 52.4 .86
Platelet baseline 6,250,000 ± 82,000 5,640,000 ± 61,000 .17
Percent platelet
After CPB 48.5 ± 9.8 68.2 ± 9.5 .01*
24 h after CPB 60.1 ± 18.6 80.2 ± 49.7 .43
SD, Standard deviation; CPB, cardiopulmonary bypass; POD, postoperative
day; NDS, neurologic deficit score; OPC, overall performance category; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehy-
drogenase; ALP, alkaline phosphatase; CK, creatine kinase; BUN, blood urea
nitrogen; SVO2, venous oxygen saturation; WBC, white blood cells. 
*P < .05.
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circuit during CPB, reduction of edema, creatine kinase
leakage, and improvement in neurologic performance
after CPB. Regarding neurologic and behavioral evalu-
ations, NDS is more discriminatory than OPC, which
may explain the greater significance observed in NDS
(Table II). Percentage platelet count immediately after
Fig 1. Near-infrared spectroscopy. A, Changes in oxygenated hemoglobin. B, Changes in deoxygenated hemo-
globin. C, Changes in cytochrome a,a3. DHCA, Deep hypothermic circulatory arrest; microMol/L) · DPF, micro-
molar · differential pathlength factor.
A
B
C
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CPB in group O demonstrated more free platelets and,
by inference, less platelet adhesion during CPB, which
may potentially increase the risk of bleeding after car-
diac surgery.
After CPB and DHCA, a “whole body inflammatory
response” occurs because of the summation of a num-
ber of initiating factors triggered by ischemia. These
include endothelial dysfunction, white blood cell acti-
vation caused by exposure to the extracorporeal circuit,
and the release of a myriad of inflammatory mediators
such as interleukins, thromboxanes, histamine, comple-
ment, and kallikrein. During reperfusion, this inflam-
matory state begins to manifest itself, for example, as
interstitial fluid accumulation and whole body edema.
It is speculated that PMNs play a pivotal role in the
events leading to reperfusion injury. The first step
involves margination of the activated PMNs during
laminar flow, followed by a loose, transient adhesion to
the vascular endothelial cell surface known as “rolling.”
The next step in this sequence is a firmer adhesion or
“sticking” of the PMNs and, finally, transmigration of
these cells through the vessel wall. Once in the
parenchymal tissue, PMNs exert their destructive
effects through the release of proteolytic enzymes (eg,
elastases and collagenases), chemotactic agents (eg,
thromboxane A2), oxygen-derived free radicals (eg,
superoxide, myeloperoxidase, and hydrogen peroxide),
and other agents.5,6
The selectin family of glycoproteins has been found
to mediate PMN “rolling,” which is a prerequisite step
for the subsequent firmer adhesion.7 P-selectin and E-
selectin are both found on the surface of activated
endothelial cells, whereas only P-selectin is usually
expressed on platelets. L-selectin, on the other hand, is
constitutively expressed mainly on PMNs. The ligand
for the L-selectin on leukocytes is thought to be a sim-
ilar oligosaccharide, although it is not completely char-
acterized.8,9 As previously mentioned, endothelial dys-
function occurs as a result of CPB/DHCA. One of the
characteristic features of endothelial dysfunction is the
expression of P-selectin. The mechanism that underlies
this process is extrusion of this pre-formed glycopro-
tein from within Weibel-Palade bodies onto the cell
surface.10 Once reperfusion is commenced, activated
PMNs come into close apposition with the endothelial
surface, and adhesion occurs through the recognition of
a common ligand, known as SLex, which is abundantly
expressed on the surface glycoproteins of PMNs and
serves as the ligand for the 2 adhesion molecules E-
selectin and P-selectin. Neither E-selectin nor P-
selectin is found on resting vascular endothelial cells.
SLex is a tetrasaccharide that contains essential
residues sialic acid and fucose.11-14 It is known that P-
selectin binds to L-selectin–bound SLex during reper-
fusion injury, whereas the roles of E-selectin are
unclear, because it is expressed only 4 to 6 hours after
cell activation.15,16
CY-1503 is a synthetic pentasaccharide that contains
SLex ligand. It was developed in an effort to block PMN
interaction competitively with both E-selectin and P-
selectin expressed on the surface of endothelial cells.17
Several in vivo reports have already shown the bene-
ficial effects of CY-1503 against ischemia/reperfusion
injury. In 1994 Lefer and associates18 first demonstrated
strong evidence that treatment with a unique carbohy-
drate analog of SLex, CY-1503 (5 mg/kg, intravenous-
ly), significantly reduced the PMN accumulation and
the degree of myocardial injury associated with 90
minutes of occlusion of the left circumflex coronary
artery and 4.5 hours of reperfusion in a dog model.
They also measured plasma levels of CY-1503 using
high pH anion exchange chromatography and indicated
that SLex is rapidly metabolized. Plasma level of CY-
1503 was 7.9 ± 0.5 m g/mL at 60 minutes of reperfusion.
The level declined to 3.4 ± 1.0 m g/mL at 120 minutes
A
B
Fig 2. A, Neurologic deficit scores. B, Overall performance
categories. All animals had same values on postoperative
days 1, 3, and 4 (1POD, 3POD, 4POD). *P < .05 versus
group C.
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of reperfusion, and they could not detect any trace of
this substance after 180 minutes of reperfusion.18
Silver and coworkers19 also reported successful reduc-
tion of infarct size beyond thrombolysis in the canine
model of an electrolytically thrombosed coronary
artery using a bolus of CY-1503 (40 mg/kg) and infu-
sion of tissue-type plasminogen activator (20 mg/kg
per minute). However, it is not clear from these short-
term studies whether CY-1503 treatment merely
delayed the onset or actually reduced the full extent of
myocardial necrosis after ischemia and reperfusion.
Gill, Kong, and Horwitz20 used a model similar to
Lefer’s to examine the effects of CY-1503 in an acute
canine model of myocardial ischemia and reperfusion.
Dogs were subjected to 90 minutes of ischemia through
occlusion of the left anterior descending coronary
artery and 48 hours of reperfusion. Five minutes before
the onset of reperfusion, dogs received CY-1503 at a
dose of 20 mg/kg. Unlike the previous reports, these
authors did not find any beneficial effects of CY-1503
in reducing myocardial infarct size nor cardiac
myeloperoxidase activity, although this may have been
because of an inadequate dose.21 They hypothesized
that CY-1503 might effectively block P-selectin bind-
ing but not the later expression of E-selectin.20
Several other ischemia/reperfusion injury models
have been developed to examine the effects of CY-1503.
Misawa and coworkers22 demonstrated significant
improvement in biochemical evidence of hepatic injury
after 90 minutes of total hepatic ischemia in a rat model
when they administered a 25 mg/kg dose of CY-1503 5
minutes before reperfusion. They also showed a signif-
icant difference in myeloperoxidase and degree of
necrosis in hepatic tissue 6 hours after reperfusion. Han
and associates23 demonstrated that CY-1503 attenuated
reperfusion injury in the rabbit ear. They concluded that
CY-1503 was efficacious only if administered in the
first hour after reperfusion, suggesting that the more
immediately available P-selectin and L-selectin partici-
pated in the PMN adhesion/injury process, whereas E-
selectin, with its delayed endothelial expression, did
not. On the other hand, Zhang and colleagues24 showed
evidence of the involvement of E-selectin in transient
major coronary artery occlusion in rats and suggested
that E-selectin might facilitate PMN adhesion and sub-
sequent cerebral ischemic cell damage.
The mechanism of protection during ischemia/reper-
fusion of exogenous SLex has not been well described.
It is possible that this compound, after ischemia/reper-
fusion injury, might compete with the binding of the
naturally occurring (endogenous) product in the PMNs,
to the expressed selectins receptor in the endothelium
or platelet. This may result in less adhesion and infil-
tration of PMNs with subsequent diminished tissue
damage. Another possibility is that CY-1503 might
block platelet/PMN adhesion and decrease the produc-
tion of PMN/platelet complexes that may be a cause of
the no-flow phenomenon after ischemia/reperfusion.
Fig 3. CY-1503 concentration in blood over time. CPB, Cardiopulmonary bypass; DHCA, deep hypothermic cir-
culatory arrest.
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Near-infrared spectroscopy in our study suggests a
trend toward improved cytochrome oxygenation in the
group receiving CY-1503. However, beyond the imme-
diate rewarming phase there is a trend toward less oxy-
genated hemoglobin and less deoxygenated hemoglo-
bin in the CY-1503 group, which does not support the
hypothesis that cytochrome oxygenation is improved
by increased cerebral blood flow. CY-1503 was associ-
ated with less whole body edema after CPB, suggesting
that the whole body inflammatory response was indeed
reduced. Fluid shifts per se might explain the more
rapid neurologic and behavioral recovery observed
with CY-1503 and is consistent with the absence of a
difference in histology between the treated and untreat-
ed groups. The importance of edema in influencing the
behavioral recovery is also supported by the absence of
a statistical difference in the near-infrared spectroscopy
findings between the 2 groups.
In conclusion, the analog of SLex CY-1503 attenuates
whole body injury after 100 minutes of DHCA at 15°C
in 5-week-old piglets.
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